Stereotactic radiotherapy for early stage non-small cell lung cancer: current standards and ongoing research.

ABSTRACT: Stereotactic body radiation therapy (SBRT) allows for the non-invasive and precise delivery of ablative radiation dose. The use and availability of SBRT has increased rapidly over the past decades. SBRT has been proven to be a safe, effective and efficient treatment for early stage non-small cell lung cancer (NSCLC) and is presently considered the standard of care in the treatment of medically or functionally inoperable patients. Evidence from prospective randomized trials on the optimal treatment of patients deemed medically operable remains owing, as three trials comparing SBRT to surgery in this cohort were terminated prematurely due to poor accrual. Yet, SBRT in early stage NSCLC is associated with favorable toxicity profiles and excellent rates of local control, prompting discussion i

SUBMITTER: Vlaskou Badra E 

PROVIDER: S-EPMC8107760 | biostudies-literature | 2021 Apr

REPOSITORIES: biostudies-literature